Tumor-specific bispecific immune cell engager
AssigneeThe Regents of the University of California
InventorsBin Liu, Scott Bidlingmaier, Yang Su
Life of this patent
Estimating the term…
Abstract
Disclosed herein are monospecific and bispecific antibodies that comprise a ALPPL2/ALPP-binding variable region. The bi-specific antibody is comprises of a monoclonal antibody targeting a tumor-specific cell surface antigen (ALPPL2/ALPP) with exquisite tissue specificity and a monoclonal antibody targeting a cell surface molecule (e.g., CD3) expressed by immune effector cells.
Claims37
An antibody comprising a variable region that specifically binds to ALPPL2 and ALPP, wherein the antibody comprises a heavy chain variable region and a light chain variable region,
- wherein complementarity determining region (CDR) 1, CDR2 and CDR3 of the heavy chain variable region are selected from the following sets:
- SEQ ID NOs:
- 20, 21, and 22;
- SEQ ID NOs:
- 23, 24, and 25;
- SEQ ID NOs:
- 26, 27, and 28;
- SEQ ID NOs:
- 29, 30, and 31;
- SEQ ID NOs:
- 32, 33, and 34;
- SEQ ID NOs:
- 35, 36, and 37;
- SEQ ID NOs:
- 38, 39, and 40;
- SEQ ID NOs:
- 41, 42, and 43;
- SEQ ID NOs:
- 44, 45, and 46;
- SEQ ID NOs:
- 47, 48, and 49;
- or
- SEQ ID NOs:
- 50, 51, and 52;
- CDR1, CDR2, and CDR3 of the light chain variable region are selected from the following sets:
- SEQ ID NOs:
- 53, 54, and 55;
- SEQ ID NOs:
- 56, 57, and 58;
- SEQ ID NOs:
- 59, 60, and 61;
- SEQ ID NOs:
- 62, 63, and 64;
- SEQ ID NOs:
- 65, 66, and 67;
- SEQ ID NOs:
- 68, 69, and 70;
- SEQ ID NOs:
- 71, 72, and 73;
- or
- SEQ ID NOs:
- 74, 75, and 76,
- with the proviso that the antibody does not have the heavy chain variable region of M25FYIA and the light chain variable region of M25FYIA.
The CAR-expressing human cell of claim 36, wherein the human cell is a T-cell, natural killer cell or a macrophage.
Dependencies are inferred from the claim text.